|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000155093 |
Summary for PTPRN2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000155093 | Gene symbol | PTPRN2 |
| Gene name | protein tyrosine phosphatase receptor type N2 | |
| HGNC | 9677 | |
| Entrez ID | 5799 | |
| Gene type | protein_coding | |
| Synonyms | PTPRN2|KIAA0387|phogrin|ICAAR|IA-2beta | |
| UniProtAcc | Q92932 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for PTPRN2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PTPRN2 | 1.90e+03 | -2.24e+00 | 7.12e-01 | -3.15e+00 | 1.62e-03 | 9.16e-03 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PTPRN2 | 3.04e+03 | -1.26e+00 | 4.71e-01 | -2.68e+00 | 7.42e-03 | 2.71e-02 | STAD |
| PTPRN2 | 1.61e+03 | 1.51e+00 | 1.98e-01 | 7.61e+00 | 2.78e-14 | 7.35e-14 | BRCA |
Top |
Sex-biased somatic mutation for PTPRN2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for PTPRN2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| GBM | cg00449390 | chr7:158586531 | CGI:chr7:158586636-158588529 | promoter,gene body | 2.94e-01 | 4.07e-01 | -2.46e+00 | 1.40e-02 | 2.97e-02 | -1.13e-01 |
| GBM | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 1.61e-01 | 2.67e-01 | -2.06e+00 | 3.98e-02 | 4.60e-02 | -1.06e-01 |
| MESO | cg22282410 | chr7:158588192 | CGI:chr7:158586636-158588529 | promoter | 1.33e-01 | 2.43e-01 | -2.59e+00 | 9.62e-03 | 2.75e-02 | -1.11e-01 |
| MESO | cg27392792 | chr7:158588194 | CGI:chr7:158586636-158588529 | promoter | 9.09e-02 | 2.08e-01 | -2.09e+00 | 3.68e-02 | 4.68e-02 | -1.17e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 2.26e-01 | 9.06e-02 | 5.66e+00 | 1.51e-08 | 1.02e-07 | 1.36e-01 |
| LUAD | cg22282410 | chr7:158588192 | CGI:chr7:158586636-158588529 | promoter | 2.65e-01 | 1.36e-01 | 3.45e+00 | 5.55e-04 | 1.18e-03 | 1.30e-01 |
| LUAD | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 3.54e-01 | 2.12e-01 | 3.31e+00 | 9.45e-04 | 1.85e-03 | 1.42e-01 |
| LUSC | cg10218605 | chr7:158586440 | CGI:chr7:158586636-158588529 | promoter,gene body | 5.65e-01 | 3.83e-01 | 2.68e+00 | 7.26e-03 | 1.08e-02 | 1.82e-01 |
| COAD | cg12348202 | chr7:158588331 | CGI:chr7:158586636-158588529 | promoter | 3.31e-01 | 2.12e-01 | 2.26e+00 | 2.41e-02 | 2.85e-02 | 1.18e-01 |
| COAD | cg18601426 | chr7:158588528 | CGI:chr7:158586636-158588529 | promoter | 4.95e-01 | 3.88e-01 | 2.82e+00 | 4.83e-03 | 8.03e-03 | 1.06e-01 |
| BLCA | cg27392792 | chr7:158588194 | CGI:chr7:158586636-158588529 | promoter | 2.16e-01 | 4.90e-02 | 2.22e+00 | 2.65e-02 | 3.05e-02 | 1.67e-01 |
| BLCA | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 3.26e-01 | 1.47e-01 | 3.07e+00 | 2.16e-03 | 4.16e-03 | 1.79e-01 |
| CHOL | cg10218605 | chr7:158586440 | CGI:chr7:158586636-158588529 | promoter,gene body | 8.65e-01 | 6.90e-01 | 2.58e+00 | 9.87e-03 | 2.15e-02 | 1.74e-01 |
| CHOL | cg19208749 | chr7:158586496 | CGI:chr7:158586636-158588529 | promoter,gene body | 5.55e-01 | 3.64e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.91e-01 |
| CHOL | cg00449390 | chr7:158586531 | CGI:chr7:158586636-158588529 | promoter,gene body | 5.61e-01 | 3.81e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.79e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg22282410 | chr7:158588192 | CGI:chr7:158586636-158588529 | promoter | 3.61e-01 | 1.62e-01 | 7.98e+00 | 1.45e-15 | 5.52e-15 | 1.99e-01 |
| BRCA | cg27392792 | chr7:158588194 | CGI:chr7:158586636-158588529 | promoter | 3.59e-01 | 1.29e-01 | 7.91e+00 | 2.62e-15 | 9.78e-15 | 2.29e-01 |
| BRCA | cg12348202 | chr7:158588331 | CGI:chr7:158586636-158588529 | promoter | 5.15e-01 | 2.56e-01 | 1.11e+01 | 1.73e-28 | 2.11e-27 | 2.59e-01 |
| BRCA | cg10218605 | chr7:158586440 | CGI:chr7:158586636-158588529 | promoter,gene body | 5.81e-01 | 3.70e-01 | 8.38e+00 | 5.08e-17 | 2.16e-16 | 2.11e-01 |
| BRCA | cg19208749 | chr7:158586496 | CGI:chr7:158586636-158588529 | promoter,gene body | 4.28e-01 | 3.05e-01 | 6.09e+00 | 1.11e-09 | 2.68e-09 | 1.23e-01 |
| BRCA | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 3.32e-01 | 1.67e-01 | 6.95e+00 | 3.77e-12 | 1.11e-11 | 1.65e-01 |
| BRCA | cg18601426 | chr7:158588528 | CGI:chr7:158586636-158588529 | promoter | 5.59e-01 | 2.64e-01 | 1.28e+01 | 1.54e-37 | 7.10e-36 | 2.95e-01 |
| BRCA | cg07920930 | chr7:158589192 | CGI:chr7:158586636-158588529 | promoter | 5.42e-01 | 3.81e-01 | 9.30e+00 | 1.38e-20 | 7.83e-20 | 1.61e-01 |
| LUAD | cg07920930 | chr7:158589192 | CGI:chr7:158586636-158588529 | promoter | 5.61e-01 | 4.40e-01 | 2.77e+00 | 5.53e-03 | 1.03e-02 | 1.21e-01 |
| HNSC | cg22282410 | chr7:158588192 | CGI:chr7:158586636-158588529 | promoter | 3.80e-01 | 1.86e-01 | 2.31e+00 | 2.10e-02 | 2.84e-02 | 1.93e-01 |
| HNSC | cg27392792 | chr7:158588194 | CGI:chr7:158586636-158588529 | promoter | 3.74e-01 | 1.78e-01 | 2.00e+00 | 4.53e-02 | 4.65e-02 | 1.96e-01 |
| KIRP | cg10554264 | chr7:158586656 | CGI:chr7:158586636-158588529 | promoter,gene body | 2.31e-01 | 1.07e-01 | 2.49e+00 | 1.29e-02 | 2.00e-02 | 1.24e-01 |
Top |
Exon skipping events with PSI in TCGA for PTPRN2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for PTPRN2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for PTPRN2 |
| TFs related to PTPRN2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PTPRN2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for PTPRN2 |
| RBPs related to ES in PTPRN2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PAAD | LIN28A | exon_skip_480828 | 1.10e+01 | 1.40e-03 | 1.15e+01 | 9.98e-01 | Female-biased |
| PTPRN2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs3110895 | chr7:153516822:T:C | - | -0.05731518501491 | 0.0159107535552596 | COAD | Female-baised eQTL |
| rs3111275 | chr7:153517366:T:C | - | -0.05731518501491 | 0.0159107535552596 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs58169200 | chr7:158476732:C:T | gene | 0.0527913983935693 | 0.014863182816915 | LUSC | Male-baised eQTL |
| rs60299315 | chr7:158472853:T:G | gene | 0.046441580861026 | 0.0428998588400439 | LUSC | Male-baised eQTL |
| rs6464281 | chr7:152902576:T:A | - | 0.0359159356514611 | 0.0471665758294569 | LUSC | Male-baised eQTL |
| rs56267319 | chr7:155249222:G:A | - | 0.0768103667914943 | 0.0214893546789081 | BLCA | Male-baised eQTL |
| rs12703118 | chr7:151345197:A:G | - | 0.0810889806619629 | 0.0455376313667209 | BLCA | Male-baised eQTL |
| rs12667281 | chr7:148940673:C:T | - | 0.04156744923512 | 0.0219932753914107 | COAD | Male-baised eQTL |
| rs7792965 | chr7:148931270:G:T | - | 0.0409784296543183 | 0.0314805724600324 | COAD | Male-baised eQTL |
| rs9691157 | chr7:148940698:T:C | - | 0.0393359652048524 | 0.0376991159906382 | COAD | Male-baised eQTL |
| rs6979674 | chr7:148930439:T:C | - | 0.0396969730417934 | 0.043379658546023 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg23684218 | |
| Position to Gene: gene | |
| Male Effect: -0.326442031192504 | |
| Female Effect: - | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg04246957 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.408036191218045 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg13661172 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.408036191218045 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg03021296 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.408036191218045 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg06781608 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.370826161927952 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg06555227 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg16477744 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg10310310 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg03361379 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg12779445 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg08791395 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg00353353 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg09434085 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg05147654 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg19509988 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg18185149 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg25366140 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg10249637 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg06018853 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg03262885 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg17316096 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg14157417 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.417603683255891 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg04207084 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: 0.216809345894618 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg10218605 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.461702073133342 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg09017928 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.460906618571094 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg18407955 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.211539021437827 | |
 | Gene ID: ENSG00000155093 |
| CpG Site: cg26967842 | |
| Position to Gene: gene | |
| Male Effect: -0.270082727387054 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23684218 | chr7:157984195 | gene | -0.326442031192504 | 1.18905285667708e-09 | -0.6462580486493961 | 6.639641895073743e-13 | PAAD |
| cg26967842 | chr7:157576466 | gene | -0.270082727387054 | 8.10844577194156e-06 | -0.32047437448816046 | 1.030821711747051e-08 | BLCA |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg04246957 | chr7:157903897 | gene | -0.408036191218045 | 1.21269326692564e-14 | -0.80881407531804 | 1.1454363510612068e-19 | PAAD |
| cg13661172 | chr7:157999408 | gene | -0.408036191218045 | 1.21269326692564e-14 | -0.80881407531804 | 1.1454363510612068e-19 | PAAD |
| cg03021296 | chr7:158267922 | gene | -0.408036191218045 | 1.21269326692564e-14 | -0.80881407531804 | 1.1454363510612068e-19 | PAAD |
| cg06781608 | chr7:157568348 | gene | -0.370826161927952 | 2.57219715490787e-11 | -0.7429628410117379 | 3.015150378450662e-15 | PAAD |
| cg06555227 | chr7:157574287 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg16477744 | chr7:157574450 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg10310310 | chr7:157574458 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg03361379 | chr7:157574467 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg12779445 | chr7:157574770 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg08791395 | chr7:157575086 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg00353353 | chr7:157579288 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg09434085 | chr7:157655727 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg05147654 | chr7:157655873 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg19509988 | chr7:157667965 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg18185149 | chr7:157734881 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg25366140 | chr7:157768469 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg10249637 | chr7:157862744 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg06018853 | chr7:157904147 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg03262885 | chr7:157917487 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg17316096 | chr7:158365526 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg14157417 | chr7:158472793 | gene | -0.417603683255891 | 1.84794276804124e-06 | -0.6009185475480496 | 3.787473268456265e-09 | PAAD |
| cg04207084 | chr7:157685154 | gene | 0.216809345894618 | 3.83331791839624e-05 | 0.34609138617555085 | 2.1475846513788025e-05 | SARC |
| cg10218605 | chr7:158586440 | gene,promoter | -0.461702073133342 | 9.83074837147842e-19 | -0.7040543821180777 | 2.602308589817418e-23 | COAD |
| cg09017928 | chr7:158317376 | gene | -0.460906618571094 | 1.2524705249384e-18 | -0.70795766366203 | 3.3465626027024356e-23 | COAD |
| cg18407955 | chr7:158317993 | gene | -0.211539021437827 | 8.80569377769827e-06 | -0.45935301441315946 | 4.850742783957389e-09 | COAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs2021742 | chr7:157588979:T:A | Distant downstream | -0.0869138769727856 | 0.0266795203805145 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs6459798 | chr7:157589043:C:T | Distant downstream | -0.0869138769727856 | 0.0266795203805145 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs73163814 | chr7:157595320:A:G | Distant downstream | -0.0869138769727856 | 0.0266795203805145 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs73163816 | chr7:157595434:C:G | Distant downstream | -0.0869138769727856 | 0.0266795203805145 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs143580115 | chr7:157594396:T:G | Distant downstream | -0.0878234082677895 | 0.0305989044361856 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs2366642 | chr7:157594403:A:G | Distant downstream | -0.0878234082677895 | 0.0305989044361856 | PAAD | Female-baised sQTL |
| exon_skip_480832 | chr7:158110828:158110915 | In-frame | rs73163815 | chr7:157595355:A:G | Distant downstream | -0.0869974220777566 | 0.0328871028854991 | PAAD | Female-baised sQTL |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of PTPRN2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
